GSK 5733584

Unknown / undisclosed

Phase 3Undisclosed / early pipeline
Phase 3underway

Evidence outlook · registrational

Ovarian Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-09-06.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Ovarian Cancer
NCT07694427 · GlaxoSmithKline
2026-10-02 – 2032-11-08 · Ovarian Neoplasms
What this study did
NCT07286266 · GlaxoSmithKline
2026-06-18 – 2030-07-22 · Ovarian Neoplasms
What this study did
Other / comorbidity
NCT07684599 · GlaxoSmithKline
2026-09-24 – 2031-09-18 · Neoplasms, Endometrial
What this study did
Phase 2 (1)
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
Phase 1 (1)
Other / comorbidity

Competitive landscape

This drug's own stage for Ovarian Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
GSK 5733584: this drugPhase 3——not yet gradedNo reviewed efficacy summary in this indication
Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack)ApprovedSmall moleculeMEK1/2 and RAF (CRAF, BRAF), FAKnot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Mirvetuximab Soravtansine (Elahere)ApprovedAntibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
NiraparibApprovedSmall moleculePARP1/2Reliable signal
NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9)
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)ApprovedSmall moleculeGlucocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Reliable signalFeatured results are non-efficacy only in this race
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
INCB123667Phase 3Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 3Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 3Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Torvutatug SamrotecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BirinapantPhase 2—IAP (inhibitor of apoptosis) proteinsnot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 2Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
StenoparibPhase 2Small moleculePARP1/2, Tankyrase 1/2not yet gradedNo reviewed efficacy summary in this indication
COM701Phase 1/2Monoclonal antibodyPVRIG (CD112R)not yet gradedNo reviewed efficacy summary in this indication
REGN5668Phase 1/2Multispecific antibodyMUC16 x CD28not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 1/2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 1/2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
27T51Phase 1Cell therapyMUC16not yet gradedNo reviewed efficacy summary in this indication
ABBV-901Phase 1UndisclosedFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 1Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
IDE-161Phase 1Small moleculePARGnot yet gradedNo reviewed efficacy summary in this indication
XmAb541Phase 1Multispecific antibodyClaudin 6 (CLDN6) x CD3not yet gradedNo reviewed efficacy summary in this indication
Luveltamab TazevibulinDiscontinuedAntibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(7 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow GSK 5733584 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Phase 1Solid Tumors, NeoplasmsRecruiting
Est. primary completion 2027-09-22 · NCT06431594 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Phase 3Neoplasms, EndometrialRecruiting
Est. primary completion 2028-02-29 · NCT07286331 · CT.gov ↗
What to watch
2029 (2)
July 2029 (1)
Phase 3Neoplasms, EndometrialRecruiting
Est. primary completion 2029-07-23 · NCT07684599 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-09-06 · NCT07694427 · CT.gov ↗
What to watch
2030 (3)
May 2030 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2030-05-21 · NCT07684612 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2030-07-22 · NCT07286266 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch

See the full readout calendar ↗